As per the citing of the National Organization for Rare Diseases (NORD) 2016 report, hepatic encephalopathy is described as a brain disorder in patients previously suffering from chronic liver ailments such as liver cirrhosis, hepatitis, and acute liver failure. If effectively diagnosed, hepatic encephalopathy occurs in almost two-thirds of the patients suffering from liver cirrhosis. Hepatic encephalopathy is categorized into three types, such as Type A (acute liver failure), Type B (portal systemic bypass without liver disease), and Type C (liver cirrhosis). The exact disease etiology is unknown, but the disease is triggered by the accumulation of toxins in the bloodstream as the diseased liver fails to neutralize the toxins. The clinical manifestations associated with hepatic encephalopathy are confusion, anxiety, lethargy, seizures, confused speech, personality changes, and poor body movements. The key factors driving the hepatic encephalopathy therapeutics market are the rising prevalence of liver disorders, the lack of nutrients in daily food intake, and increasing public health awareness resulting in early diagnosis and treatment.
The diagnosis of hepatic encephalopathy includes blood tests, a liver function test, the detection of serum ammonia levels, and an encephalogram of the brain to measure the electrical activity of the brain. There are numerous therapeutic approaches to manage the severity of hepatic encephalopathy, but the reduction of plasma ammonia is the most preferred strategy. Lactulose is the first line of treatment, as it changes the acidity of the stool in order to reduce the production of ammonia by killing intestinal bacteria. Probiotics and thiamine are useful in the treatment of hepatic encephalopathy by increasing the expulsion of ammoniagenic bacteria by causing the bowel to get fermented by colonic bacteria to produce lactic and acetic acid. In 2010, the USFDA approved Rifaximin for the treatment of hepatic encephalopathy by acting on the microorganisms in the intestinal tract that produce ammonia.
The hepatic encephalopathy therapeutics market is classified as follows:
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Rest of Latin America
- Middle East and Africa
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Key players identified for the hepatic encephalopathy market include:
ASKA Pharmaceutical Company Ltd., COSMO Pharmaceuticals, Fresenius Kabi AG, Mallinckrodt Pharmaceuticals, Lupin, Salix Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd., Valeant Pharmaceuticals International, Inc., and other notable players
This report offers the following:
- A market assessment is conducted by considering 2017 as the base year; the market size and compounded annual growth rate (CAGR) is given for the forecast period from 2018 to 2026.
- For the scope of the report, an attractive investment proposition is given for the geography segments by understanding the prevailing market trends in the hepatic encephalopathy therapeutics market.
- In the company profiles section, product portfolios of different manufacturers are listed. Vital information such as mergers and acquisitions, strategic collaborations, and the financial health of the key players is also included.